Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.

In the ADAPT study, use of naproxen 220 mg twice daily was associated with a 60% increase in the risk of MI, congestive heart failure, cerebrovascular accident or transient ischemic attack compared with placebo (HR 1.40, 95% CI 1.12–1.75; P <0.05), but the higher rate of CV events in the celecoxib group (200 mg twice daily) did not reach statistical significance (HR 1.10, 95% CI 0.67–1.79). 47 However, it should be noted that safety was not a prespecified end point in this trial.

also in 111,027 other papers